SOURCE: Milestone Scientific, Inc.

October 14, 2015 07:30 ET

Milestone Scientific's Epidural & Intra-Articular Subsidiary to Present Initial Results of Clinical Trials for Its Epidural Instrument at Event for Leading Anesthesiologist and Key Opinion Leaders

LIVINGSTON, NJ--(Marketwired - October 14, 2015) - Milestone Scientific Inc.'s (NYSE MKT: MLSS) Epidural & Intra-Articular (IA) Subsidiary today announced that it will host an event on November 20th in Miami for a group of leading anesthesiologists and key opinion leaders in the field where it plans to present the interim results from its COMPASS clinical study for the epidural instrument. Milestone Scientific's Epidural & IA Subsidiary will also issue a press release following the event which will include data reviewed with the anesthesiology and pain management experts. The presentation will share how the CompuFlo® Epidural platform technology impacted the safety of epidural procedures and operational efficiencies, and address the potential for malpractice risk reduction.

Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We look forward to unveiling the initial results of the clinical trials to a group of leading industry experts and the public at large. We believe the epidural instrument has the potential to transform an industry that has been plagued with safety concerns with one of the highest rates of malpractice in medicine. We believe these instruments represents the future of drug delivery."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • David Waldman or Natalya Rudman
    Crescendo Communications, LLC
    Email: mlss@crescendo-ir.com
    Tel: 212-671-1020